Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALNPCSsc a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia

Alnylam Earns $10 Million Milestone from The Medicines Company Companies Expect to Present Initial Clinical Results in Mid2015 Alnylam Pharmaceuticals Inc. Nasdaq ALNY a leading RNAi therapeutics company and The ...